BTK inhibitors

positive negative up down good bad mixed
Biotech

Sanofi lifts lid on data behind tolebrutinib’s mixed MS studies

Sanofi linked the BTK inhibitor to a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive MS.
Nick Paul Taylor Sep 20, 2024 7:07am
plan B fail reroute road path trail miss

Sanofi's tolebrutinib fails 2 of 3 late-stage MS trials

Sep 2, 2024 1:00am
An arrow incrementally going up stairs before pointing straight up Blue background

Sanofi nails phase 3 LUNA landing, sparking race to regulators

Apr 23, 2024 2:23am
ducks in a row line up follow leader

Novartis lines up another potential indication for BTK inhibitor

Mar 9, 2024 12:00pm
end of the road road block shut down closed blocked

Merck KGaA drops evobrutinib in wake of double phase 3 fail

Mar 7, 2024 9:54am
Sanofi

Sanofi BTK inhibitor readout in chronic hives sets up ph. 3 push

Feb 26, 2024 10:35am